Lupin is currently trading at Rs. 750.90, up by 12.55 points or 1.70% from its previous closing of Rs. 738.35 on the BSE.
The scrip opened at Rs. 744.00 and has touched a high and low of Rs. 757.05 and Rs. 735.60 respectively. So far 26755 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 697.30 on 19-Jun-2019.
Last one week high and low of the scrip stood at Rs. 757.05 and Rs. 711.60 respectively. The current market cap of the company is Rs. 34117.26 crore.
The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.66% and 14.38% respectively.
Lupin’s American subsidiary -- Lupin Pharmaceuticals Inc. is recalling 39,216 bottles of Lisinopril and Hydrochlorothiazide tablets USP, 10 mg/12.5 mg, 100 tablet bottle manufactured at its Pithampur facility from the US market. The reason for the recall is presence of foreign substance; product complaints received related to brownish/blackish stains on the tablets and brownish/blackish powder observed inside the bottles. The tablets are used for treatment of hypertension.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1933.60 |
| Dr. Reddys Labs. | 1271.85 |
| Cipla | 1438.30 |
| Zydus Lifesciences | 1153.50 |
| Lupin | 2513.95 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: